Scientists understood how to deceive metabolism for weight loss

The scale stuck in the same number over months?

Losing weight can become much harder after a certain point because cutting many calories can push your body into “hunger mode”, slowing your metabolism and maintaining your fat instead of burning it for fuel.

Even people with drugs like Ozepic and Wegovy have discovered that their progress for weight loss seems to fall after 20% shedding in 25% of their weight – a phenomenon known as “Plateau Ozepic”.

Now, a new study from the University of Southern Denmark offers some hope for changing this disappointing reality.

Main author Kim Ravnskjaer, a molecular professor of biology at the university, admitted that losing weight “usually goes well at first, but while people lose some of the weights they intend to shed, their progress is stuck because the body’s metabolism fits.”

This new study suggests that we may be able to control this metabolic adaptation who would be a general player.

“If we could develop a drug that helps maintain fat or burn sugar at its original high level along with weight loss treatments, people may continue to lose weight beyond the usual plain,” he said.

Ravnskjaer and his team explored the role of a genius called PLVAP in the liver of mice.

They were aware of previous studies that people born without this gene tend to have problems with their lipid metabolism – the processes with which the body breaks, transports and uses fats for energy, storage and cell functions – and they wanted to explore the connection.

What they found was that this gene is largely responsible for controlling the metabolic shift of burnt sugar in fat while in the “hunger mode”.

When the genius was disabled in laboratory mice, the liver failed to recognize the state of fasting and continued sugar metabolism.

This signal can have a way to “deceive” the liver to speed up metabolism.

“If we can control the burning of sugar and liver fat, we can also increase the effectiveness of medicines for losing weight and diabetes,” Said Ravnskjaer.

Another exciting discovery was that rats showed no adverse effects throughout the experiment.

In fact, they seemed to have lower blood sugar levels and improved insulin sensitivity.

“It is known that raised blood sugar can lead to chronic complications for people with type 2 diabetes,” Ravnskjaer said. “Understanding PLVAP can help diabetics better regulate their blood sugar in the future.”

The findings of the study were published Monday in the journal Cell Metabolism.

The research has been limited to rats so far, and human evidence is still a way away.

“It is a long way from penetrating mouse experiments to bring a drug to the market – but this is definitely the potential in our research,” he said.